Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Carcinoma, Hepatocellular 147Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 31Neoplasms 28Cholangiocarcinoma 26Endometrial Neoplasms 19Thyroid Neoplasms 17Liver Neoplasms 17Melanoma 15Stomach Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Biliary Tract Neoplasms 13Recurrence 9Neoplasm Metastasis 9Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 5Thyroid Carcinoma, Anaplastic 5Small Cell Lung Carcinoma 5Neuroendocrine Tumors 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma 4Adenocarcinoma 4Thyroid Cancer, Papillary 3

Interventions

Filgrastim 20Etoposide 20Ifosfamide 19Cyclophosphamide 18Vincristine 13Radiotherapy 13Doxorubicin 13Peripheral Blood Stem Cell Transplantation 12Melphalan 12Carboplatin 10Busulfan 9Topotecan 8Temozolomide 8Magnetic Resonance Spectroscopy 8X-Rays 6Thiotepa 6Phantoms, Imaging 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 5trioctyl phosphine oxide 4Mesna 4Docetaxel 4Dactinomycin 4temsirolimus 3etoposide phosphate 3cixutumumab 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × lenvatinib × Clear all
NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Eisai Inc.

Phase 1/2 Completed
64 enrolled 29 charts
CNSSarcoma

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡